Syndax Pharmaceuticals SNDX Stock
Syndax Pharmaceuticals Price Chart
Syndax Pharmaceuticals SNDX Financial and Trading Overview
| Syndax Pharmaceuticals stock price | 10.45 USD |
| Previous Close | 14.29 USD |
| Open | 14.55 USD |
| Bid | 8.08 USD x 200 |
| Ask | 13.14 USD x 200 |
| Day's Range | 10.14 - 14.69 USD |
| 52 Week Range | 10.14 - 25.59 USD |
| Volume | 11.15M USD |
| Avg. Volume | 2.03M USD |
| Market Cap | 916.49M USD |
| Beta (5Y Monthly) | 0.45 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.37 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 37.27 USD |
SNDX Valuation Measures
| Enterprise Value | 1.44B USD |
| Trailing P/E | N/A |
| Forward P/E | -14.033638 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 3.163815 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 4.966 |
| Enterprise Value/EBITDA | -8.054 |
Trading Information
Syndax Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 0.45 |
| 52-Week Change | -5.36% |
| S&P500 52-Week Change | 11.36% |
| 52 Week High | 25.59 USD |
| 52 Week Low | 10.14 USD |
| 50-Day Moving Average | 16.95 USD |
| 200-Day Moving Average | 20.17 USD |
SNDX Share Statistics
| Avg. Volume (3 month) | 2.03M USD |
| Avg. Daily Volume (10-Days) | 3.22M USD |
| Shares Outstanding | 90.03M |
| Float | 81.12M |
| Short Ratio | 8.03 |
| % Held by Insiders | 1.67% |
| % Held by Institutions | 125.95% |
| Shares Short | 18M |
| Short % of Float | 20.34% |
| Short % of Shares Outstanding | 20.00% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | September 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -72.31% |
| Operating Margin (ttm) | -50.29% |
| Gross Margin | -2.025% |
| EBITDA Margin | -61.66% |
Management Effectiveness
| Return on Assets (ttm) | -17.94% |
| Return on Equity (ttm) | -426.42% |
Income Statement
| Revenue (ttm) | 289.68M USD |
| Revenue Per Share (ttm) | 3.27 USD |
| Quarterly Revenue Growth (yoy) | 81.59% |
| Gross Profit (ttm) | -5868000 USD |
| EBITDA | -178622000 USD |
| Net Income Avi to Common (ttm) | -209483008 USD |
| Diluted EPS (ttm) | -2.37 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 437.26M USD |
| Total Cash Per Share (mrq) | 4.86 USD |
| Total Debt (mrq) | 589.41M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 4.691 |
| Book Value Per Share (mrq) | -0.191 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -177359008 USD |
| Levered Free Cash Flow (ttm) | -113034128 USD |
Profile of Syndax Pharmaceuticals
| Country | United States |
| State | NY |
| City | New York |
| Address | 730 Third Avenue |
| ZIP | 10017 |
| Phone | 781 419 1400 |
| Website | https://syndax.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 298 |
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Q&A For Syndax Pharmaceuticals Stock
What is a current SNDX stock price?
Syndax Pharmaceuticals SNDX stock price today per share is 10.45 USD.
How to purchase Syndax Pharmaceuticals stock?
You can buy SNDX shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Syndax Pharmaceuticals?
The stock symbol or ticker of Syndax Pharmaceuticals is SNDX.
Which industry does the Syndax Pharmaceuticals company belong to?
The Syndax Pharmaceuticals industry is Biotechnology.
How many shares does Syndax Pharmaceuticals have in circulation?
The max supply of Syndax Pharmaceuticals shares is 90.03M.
What is Syndax Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Syndax Pharmaceuticals PE Ratio is now.
What was Syndax Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Syndax Pharmaceuticals EPS is -2.37 USD over the trailing 12 months.
Which sector does the Syndax Pharmaceuticals company belong to?
The Syndax Pharmaceuticals sector is Healthcare.
Syndax Pharmaceuticals SNDX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
|
- | |||||
US Tech Composite
IXIC
US
|
25736.51 USD — |
+1.44
|
8.6B USD — | 25602.14 USD — | 26048.83 USD — | — - | 8.6B USD — |
|
US Tech US 700 Small Cap Index
NQUS700SC
US
|
3102.06 USD — |
+1.97
|
— — | 3074.04 USD — | 3118.55 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
|
US Tech Global Select Market Com
NQGS
US
|
12673.5 USD — |
+1.45
|
— — | 12605.12 USD — | 12829.58 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
7463.68 USD — |
+2.71
|
— — | 7226.62 USD — | 7464.28 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1422.9 USD — |
+3.66
|
— — | 1382.57 USD — | 1422.97 USD — | — - | — — |
